Ryan Moy
@RyanMoyMDPhD
Followers
553
Following
2K
Media
48
Statuses
247
Asst Professor, GI oncologist @columbiacancer. Former med onc fellow @sloan_kettering. 🏳️🌈 Runner 🏃🏻, 🦮🌿 dad.
New York, NY
Joined July 2019
Congratulations to the Matterhorn study team. FDA approval independent of PD-L1 status. https://t.co/WPR8h4o4gf
fda.gov
FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma
1
12
45
Read how Columbia’s newly appointed Director of Hepatobiliary Cancers and Director of Liver Transplant Oncology Aiwu Ruth He, MD, PhD, is bridging the lab and the clinic to transform liver cancer care at @ColumbiaMed / @ColumbiaSurgery
cancer.columbia.edu
Aiwu Ruth He, MD, PhD talks about how she’s bridging the gap between lab and clinic, expanding liver cancer clinical trials, and improving outcomes for patients with liver cancer.
3
4
14
We have seen the mountain ⛰️ top! MATTERHORN OS #ESMO25 OS continues to ⬆️over time (~7% 3y) Benefit independent of PD-L1 Enough now to adopt as SOC? #ESMOAmbassadors
1
35
102
5 miles for my 5th @velocity_ride Raising funds for our patients and cancer research: https://t.co/dDtc8ARtWl
0
2
11
Pictures from my @velocity_ride on this beautiful fall day - grateful for the ability to contribute and raise $ for our patients and for cancer research @columbiacancer - https://t.co/aQeMq2pc9y
1
3
13
CCNE1 amplification (~4–10% of esophagogastric cancers) is linked to CIN, poor prognosis & resistance. At #DAVAGI, @RyanMoyMDPhD @columbiacancer discussed PKMYT1 inhibition with lunresertib(RP-6306), showing preclinical activity & synergy with anti-PD1.
0
2
5
Diffuse gastric cancer (DGC) lacks validated targets & carries poor outcomes. @RyanMoyMDPhD @columbiacancer presents data on FAK inhibition + MAPK blockade as a new strategy. Avutometinib(RAF/MEK clamp) + defactinib (FAK inhibitor) show synergy in DGC models. #DAVAGI
0
1
5
Multi-omic characterization of EOEGC (<50 years) 🔗 https://t.co/pd7etAe5f0 📊 5,175 pts (EOEGC N= 530) 👩⚕️ More in female, Black, Asian, Hispanic/Latino 🧬 ↑ CDH1 mut; CNAs: FGFR2, CCNE1, MYC; ARHGAP26 fusion 🛡️ ↓ MSI-H, TMB-H, PD-L1+ 🦠 ↑ M2, ↓ M1 📈 EMT & coag ↑
1
5
20
Examining periop Checkpoint inhibitor benefit in gastro-esophageal cancer... https://t.co/lNe0glc9aD Led by very talented @josephjzhao and Kennedy Ng. @sundar__raghav
0
10
36
Excited to share our study led by fellow Lawrence Wu, focusing on the molecular characterization of early-onset esophagogastric cancer. We explore transcriptional profiles, immune microenvironment, and real-world survival outcomes. https://t.co/xDD3lwWpuy
0
1
14
Dr. Lawrence Wu presenting our work on clinicogenomic profiling of signet ring carcinoma across organ sites. Awarded both an ASCO Conquer Cancer Foundation Merit Award and CAHON Young Investigator Award! #ASCO25
2
0
18
Super⭐️ oncology fellow Lawrence Wu presenting work on TEAD inhibition in diffuse gastric cancer #AACR
0
2
14
Sungjoo Jang presenting our work on PKMYT1 inhibition in CCNE1-amplified gastric cancer. Thankful for grant funding from AACR and Debbie’s Dream Foundation to support this work! @StomachCancer_
0
0
3
Our analysis of Claudin18.2 expression in gastroesophageal adenocarcinoma in a diverse patient cohort with higher positivity in Hispanic patients. Presented by Dr. Sara Wallam who is applying for heme/onc fellowship this cycle!
0
0
6
Running the CUIMC Team Relay Marathon for team Cure Stomach Cancer with Moy and Ryeom lab members
1
0
11
Look at this!! 👀 New trends in cancer cases show a major change in #StomachCancer in women especially. We need more research to understand the causes for this. #CancerResearch @theNCI @NoStomach4Cancr @StomachCancer_ @UMGCCC
3
10
54
Always a pleasure to chair a meeting with @YJanjigianMD! Please join us for our 1st combined solid tumor hybrid meeting: Great Debates in Solid Tumors. @GreatDebatesCME Register: https://t.co/hIncPULJpg 🤩@NVijayvergiaMD #NET at 10AM today. #Cancer #cancerresearch
1
3
15
Excited to share biomarker analysis of CM649 @NatureMedicine @YJanjigianMD Nivo benefit was enriched in TMB-H> EBV and GS > CIN. Targeted tx is needed for CIN. Nivo+Ipi benefit was seen in Treg↑ (FOXP3+CCR8), supporting Treg or CCR8 targeting tx in GC. https://t.co/ftaIzwDi93
nature.com
Nature Medicine - Exploratory biomarker analyses of the phase 3 CheckMate 649 trial show that in patients with advanced gastroesophageal cancer, KRAS alterations were associated with greater...
7
30
104